Publications by authors named "S Guerzoni"
Article Synopsis
- Migraine with aura (MwA) is a painful disorder marked by neurological symptoms, predominantly visual, with unclear causes involving the trigeminovascular system and cortical spreading depression.* -
- The study analyzed data from 272 MwA patients, finding that most experienced typical aura symptoms, especially visual auras, and some reported relapses within 24 hours.* -
- Common treatments for aura included triptans, non-steroidal anti-inflammatory drugs, and nutraceuticals, which may help improve clinical management and understanding of MwA.*
We evaluated response to VEN/HMA in 46 patients with acute myeloid leukemia (AML) characterized by extramedullary disease (EMD). Median age was 65 (range, 19-81) years. Patients had a median of two EMD sites (range, 1-5) and 35 (76%) patients had concurrent bone marrow involvement.
View Article and Find Full Text PDFBackground And Purpose: Although there is extensive evidence about the safety of monoclonal antibodies against calcitonin gene-related peptide (anti-CGRP mAbs) in combination with traditional drugs, scarce data are available on the safety of their combination with other mAbs. This study aimed to evaluate the 6-month effectiveness and tolerability of anti-CGRP mAbs in combination with other mAbs for different diseases.
Methods: Patients included in the Italian Headache Registry and treated concomitantly with an anti-CGRP mAb and another mAb were included.
Background: While monoclonal antibodies (mAbs) targeting the CGRP pathway have revolutionized migraine management due to their improved tolerance and adherence, concerns remain about their potential impact on blood pressure (BP), especially in older patients, due to CGRP-mediated vasodilation blockade. Given the growing use of these therapies in older populations, assessing their cardiovascular (CV) safety is of paramount importance.
Methods: This multicentric observational prospective study focused on migraine sufferers aged ≥ 60 who began erenumab, galcanezumab, or fremanezumab for prevention.